GlassScriptPhysician profile
Flana Rose Levando
NPI 1194341248
$3,374.18
in general payments reported to CMS, 2019-2025
13 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 88% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.70 · 2021: $121 · 2022: $149 · 2023: $682 · 2024: $1,131 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $988.16 | 2022-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $475.13 | 2023-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $380.55 | 2022-2025 | |
| Alcon Vision LLC | $329.85 | 2023-2025 | Tryptyr, Clareon, Rocklatan |
| Glaukos Corporation | $270.27 | 2024 | Ce-Marked Kxla System |
| Harrow Eye, LLC | $259.88 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $168.49 | 2021-2024 | Cequa |
| Dompe US, INC. | $163.51 | 2024-2025 | Oxervate |
| Amgen INC. | $159.75 | 2025 | Tepezza |
| Coopervision INC. | $102.58 | 2023-2025 | Misight Contact Lens, Myday Contact Lens |
| Biotissue Holdings INC. | $39.70 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $21.69 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $14.62 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flana Levando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.